TR Dizin İndeksli Yayınlar Koleksiyonu / TR Dizin Indexed Publications Collection
Permanent URI for this collectionhttps://hdl.handle.net/20.500.14365/4
Browse
14 results
Search Results
Article İnfluenza A/B Virüs ve RSV Validasyon Standartlarının Dijital PCR ile Kantitasyonu(Ankara Microbiology Soc, 2025-07-26) Sayıner, Ayca Arzu; Bulgurcu, AlıhanMikrobiyolojik tanı laboratuvarlarında kullanılacak tanı testleri için kantitatif standartların kullanıldığı yöntem doğrulama (verification) veya geçerli kılma (validation) çalışmaları gereklidir. Nükleik asit testlerinde sentetik nükleik asit veya plazmit yerine tam virüs içeren standartların kullanılması; ekstraksiyon, revers transkripsiyon ve amplifikasyonu içerecek şekilde tanı testinin tüm basamaklarının gerçek yaşam koşullarında değerlendirilmesini sağlar. Solunum yolu virüsleri için nükleik asit testlerine yönelik ticari kantitatif standart materyaller sınırlıdır. Bu çalışmada; influenza A virüs (infA), influenza B virüs (infB) ve respiratuvar sinsityal virüs (RSV) için dijital polimeraz zincir reaksiyonu [digital polymerase chain reaction (dPCR)] kullanılarak, kantitatif nükleik asit standartları geliştirilmesi amaçlanmıştır. Çalışmada; RSV, infA, infB RNA pozitif olduğu bilinen nazofarengeal sürüntü örneklerinin havuzlanmasıyla hazırlanan örneklerdeki viral nükleik asit miktarı, ticari primer/prob setleri (Qiagen, Almanya) kullanılarak dPCR (QIAcuity, Qiagen) yöntemiyle belirlenmiştir. Nükleik asit ekstraksiyonu, ticari bir kit (Xi’an Tianlong Science&Technology Co, Çin) kullanılarak yapılmıştır. dPCR yönteminin infA, infB ve RSV için analitik duyarlılık (LoD) ve kantitasyon alt sınırı (LoQ), çalışma içi ve çalışmalar arası tekrarlanabilirliği ve doğrusallığı belirlenmiştir. dPCR ile çalışılan örnekler, kantitatif revers transkripsiyon gerçek zamanlı [quantitative reverse transcription realtime (qrRT)] PCR (qRT-PCR) ile de çalışılarak Ct değerleri belirlenmiştir. Ct değerleri ile dPCR-kantitasyon sonuçları arasındaki ilişki lineer regresyon ile değerlendirilmiştir. İstatistiksel analiz GraphPad Prism 10.4.0 (GraphPad, ABD) ve Excel Analysis ToolPak kullanılarak yapılmıştır. İnfA, infB ve RSV için dPCR yönteminin LoD değerleri sırasıyla 93.75, 15.59 ve 26.23 kopya/mL olarak belirlenmiştir. dPCR yönteminin çalışma içi tekrarlanabilirliği (varyasyon katsayısı, %CV), düşük viral yükü olan örneklerde daha yüksek olmak üzere 0.06-7.97 arası saptanmıştır. Çalışmalar arası tekrarlanabilirlik 0.73-5.41 olarak bulunmuştur. İnfA ve infB için 3-4 log10, RSV için 7 log10 aralığında dilüsyonlar ile yapılan doğrusallık analizinde her üç virüs için de r 2≥ 0.99 olarak bulunmuştur. dPCR ile ölçülen konsantrasyonların, qRT-PCR Ct sonuçları ile korele olduğu saptanmıştır. dPCR ile qRT-PCR testlerinin çalışma içi ve çalışmalar arası tekrarlanabilirlik sonuçları karşılaştırıldığında, dPCR’nin %CV değerinin anlamlı olarak daha düşük olduğu saptanmıştır (p= 0.0312). Çalışma sonuçları dPCR yönteminin, kantitatif nükleik asit standartları elde etmede tekrarlanabilirliği yüksek ve güvenilir bir yöntem olduğunu göstermiştir. Elde edilen kantitatif standartlar ile viral yük belirlemeye yönelik tanı yöntemleri geliştirmek ve/veya bu tür testlerin yöntem onayı analizlerini yapmak mümkündür. Sonuç olarak çalışmada, havuzlanmış hasta örnekleri kullanılarak dPCR yöntemiyle infA, infB ve RSV için güvenilir kantitatif nükleik asit standartlar elde edilmiş ve dPCR yönteminin performans analizleri gerçekleştirilmiştir. Bu çalışma, dPCR ile kantitatif viral nükleik asit standartlarının üretimine bir örnek olmuştur.Letter Citation - WoS: 1Citation - Scopus: 1About The Article Titled “a Different Scintigraphic Perspective On The Systolic Function Of The Left Ventricle-1” [“sol Ventrikül Sistolik Fonksiyonuna Sintigrafik Olarak Farklı Bir Bakış Açısı-1” Başlıklı Makale Hakkında](Galenos Publishing House, 2024-02-23) Taşçı, Cengiz; Tascs, Cengiz[No abstract available]Article Citation - WoS: 7Citation - Scopus: 7Effectiveness of a Program To Raise Awareness About Pneumococcal Vaccination Among Physicians and Patients With Chronic Respiratory Diseases: a Multicenter Cohort Study(AVES, 2024-08-27) Karakurt, Z.; Yalnız, E.; Altın, S.; Oruç, Ö.; Uslu, Ö.; Veske, N.Ş.; Kılınç, O.; Sayıner, Abdullah; Kul, Seval; Şimşek, NurdanOBJECTIVE: There is a need to increase patient and clinician awareness on the effectiveness of pneumococcal vaccination in at-risk groups. The aim of the study was to evaluate the effect of reminders for physicians and patients using the vaccination tracking system created in the hospital information management system (HIMS) on the vaccination rate, and the effect of pneumococcal vaccination on pneumonia-related hospitalization and mortality over a 12-month period. MATERIAL AND METHODS: This prospective observational cohort study was undertaken during a 2-year period in 3 tertiary care cen-ters. Patients were followed up for 12 months following vaccination, and hospital admissions and mortality were recorded via HIMS. During the campaign, HIMS transmitted pneumococcal immunization reminder messages in accordance with guideline recommendations to physicians’ computers and patients’ mobile phones. Educational posters on pneumococcal vaccination were posted in outpatient clinics. Regular seminars on the evidence for pneumococcal vaccination were organized. All patients who were hospitalized during the follow-up period for chronic obstructive pulmonary disease (COPD), asthma, lung cancer, or pneumonia were analyzed in relation to their vaccination history regarding clinical outcomes. RESULTS: A total of 29 530 patients were included in the study. During the study period, the annual vaccination rate increased by 74.4% and reached 4.8% in 3 hospitals (P = .001). The rates were 3.9% in patients older than 65 years without comorbidities and 5.2% in those with COPD and asthma (P = .002). In pneumococcal vaccine recipients, pneumonia-related hospital mortality was lower (relative risk (RR) = 0.19, CI 0.09-0.35, P < .001). CONCLUSION: It is possible to raise the rate of pneumococcal vaccination through awareness campaigns. Individuals with COPD and asthma are more willing to receive pneumococcal vaccination. Among patients hospitalized for pneumonia, prior pneumococcal vaccination is associated with lower mortality. © Author(s).Article Citation - WoS: 2Differences in the Differential Expression of Micrornas Between Patients With Familial Multiple Sclerosis and Those With Sporadic Multiple Sclerosis(Galenos Publ House, 2023-12-28) Güllüoğlu, Halil; Uysal, Hasan Armağan; Poyraz, Turan; Altun, Zekiye; Kaya, Derya; Özcelik, Pınar; İdiman, Egemen; Poyraz, TuranObjective: Multiple sclerosis (MS) is a heterogeneous disease with clinical and immunological features. Most MS cases occur sporadically, but a considerable proportion of patients have a family history of MS. The etiology and pathophysiology of MS remain unclear. Recent epidemiological and gene expression studies have indicated that dysregulation of microRNAs (miRNAs) may play a role in MS pathogenesis. This study aimed to evaluate the differential expression of miRNAs in sporadic MS (sMS) and familial MS Materials and Methods: This cross-section, single-center study was conducted in 20 FMS and 10 sMS patients and 8 healthy controls. The patients were in the remission. In total, 2,549 miRNA genes were screened in the blood mononuclear cells from the whole blood samples of MS patients depending on miRBase 21. Differential expression of miRNAs in MS patients was identified compared with the control group, and miRNAs with a fold change >= 2 were validated using reverse transcription-polymerase chain reaction. Differentially expressed miRNAs were then compared between FMS and sMS patients. Results: Initial findings showed that miR-5100 and hsa-miR-16-2-3p were increased and miR-432-3p was decreased in FMS compared with sMS, whereas miR-548-aa, hsa-miR-142-3p, and miR-451-b were increased in both sMS and FMS, but miR-548-v was increased only in sMS. Some miRNAs showed the same expression patterns in both groups. Conclusion: Differential expression of certain miRNAs may be a useful biomarker in the diagnosis of MS. This study showed that miRNAs may discriminate between FMS and sMS cases and MS subtypes, as indicated in earlier studies.Article Citation - WoS: 1Citation - Scopus: 1Shotgun Lipidomics Elucidates the Lipidome Alterations of the Mcl-1 Inhibitor S63845 in Aml Cell Lines With a Focus on Sphingolipids(Istanbul University Press, 2022-12-30) Yandım, Melis Kartal; Bilgin, MesutObjective: Acute myeloid leukemia (AML) is a vigorous type of leukemia requiring effective treatment. Myeloid cell leukemia-1 (Mcl-1) is an anti-apoptotic molecule that is upregulated in AML and is studied as a target for treatment. The specific Mcl-1 inhibitor, S63845, has antiproliferative effects on AML cells. Bioactive sphingolipids have crucial roles in cells and regulate Mcl-1 stability. This study aimed to elucidate the changes in lipid profiles of AML cell lines in response to Mcl-1 inhibitor S63845 treatment, with a special focus on sphingolipids. Materials and Methods: The cytotoxic effects of S63845 were identified in the AML cell lines MV4-11, HL60, and KG1 using the MTT cell proliferation assay. Lipidome analysis was conducted by quantitative shotgun lipidomics covering 378 individual lipid species in 26 classes within the major lipid categories. Results: The IC50 values of S63845 have been calculated as 7 nM for MV4-11, 53 nM for HL60, and 479 nM for KG1. The lipidome results reveal the S63845 treatment to increase ceramide (Cer) levels in the MV4-11 and KG1 cell lines at the expense of downstream sphingolipids while increasing the hexosylceramide (HexCer) levels in the HL60 cell line at the expense of the Cer and sphingomyelin (SM). Conclusion: This study showed S63845 to be able to suppress cell proliferation by altering lipid compositions in AML cell lines. More importantly, the study suggested S63845 to differentially affect the lipid profiles of AML cell lines.Article Citation - Scopus: 3Clinical Impact of Hepatitis C Virus Genomic Variations(Ankara Microbiology Society, 2015-10-08) Ergünay K.; Abacioglu H.; Ergünay, Koray; Abacioglu, HakanHepatitis C virus (HCV) is a globally-dispersed agent of chronic hepatitis with a significant public health threat, affecting over 110 million individuals throughout the world. The increased risk for chronicity after exposure and the lack of a protective vaccine make HCV is a leading infectious cause of cirrhosis, liver failure requiring transplantation and hepatocellular carcinoma. The replicative process and infection dynamics in the host enable HCV to generate an array of closely-related but non-identical genetic variants known as quasispecies in the infected individuals. Pathogenesis and outcome in HCV infections are directly affected by the virus genetic heterogeneity, reflected as the emergence of quasispecies in infected individuals. The evolution of these highly-diverse viral populations in the host directly influences the disease course, via providing a pool of variants capable of resuming viral replication under extrinsic and/or intrinsic selective pressures. Viral quasispecies go through several alterations during the course of the infection, and provide a background for the selection of escape mutants from the host humoral and cell-mediated immune responses and antiviral treatment. Supported by the robust next generation sequencing techniques, recent studies have provided significant insights on the genomic diversity and progression as well as on the origin and the epidemiology of HCV. This review provides an overview of the mechanisms of HCV genetic variability, and the interactions with the host, that affects clinical disease, covering viral and host determinants of humoral and cell-mediated immune responses, alterations during the early and late stages of the infection and disease progression leading to chronicity. In addition, current findings in virus evolution and epidemiology were briefly interpreted from the inter-species and population perspectives. The impact of viral genomic heterogeneity on antiviral treatment in the era of direct-acting agents is also discussed, along with an overview of current methods employed for the characterization of viral diversity.Article Citation - WoS: 4Retrospective Evaluation of Candidemic Patients Among General Surgery Department in a Tertiary Care University Hospital(Turkish Surgical Assoc, 2019-09-23) Onal, Ugur; Metin, Dilek Yesim; Karaca, Can; Polat, Suleyha Hilmioglu; Ersin, Sinan; Tasbakan, Meltem IsikgozObjective: Candida species are among the most important causes of hospital acquired blood borne infections, and with high rates of mortality and morbidity, these infections are still a major problem today. History of gastrointestinal surgery, administration of total parenteral nutrition and/or wide spectrum antibiotics and immune suppression following organ transplantations are considered serious risk factors for these infections. This study aimed to evaluate the patients from our general surgery department with diagnosed candidemia; by means of strain, treatment and prognosis. Material and Methods: Patients with positive blood cultures for Candida species who were treated in the wards and Ege University Faculty of Medicine general surgery department of surgical intensive care units of our between 2012 and 2017 were retrospectively analyzed by means of strain, treatment and prognosis. Results: A total of 50 patients were enrolled in the study. Mean age was 58.96 years and 54% of the patients were female. There were nine patients with organ transplantation (four liver and five kidney transplantations), six with intestinal perforation and three with anastomotic leakage. Isolated strains were Candida albicans (36%; 18/50), Candida tropicalis (14%; 7/50), Candida glabrata (12%; 6/50), Candida parapsilosis (8%; 4/50), Candida kefyr (6%; 3/50), Candida krusei (4%; 2/50), Candida pulcherrima (2%; 1/50), Cryptococcus neoformans (2%, 1/50), Geotrichum capitatum (2%, 1/50), Candida spp. (unidentified, 14%; 7/50) with decreasing frequency. The highest antifungal sensitivity rates (> 90%) were measured for amphotericin B, voriconazole and echinocandins among all isolates. One-month mortality rate was 43.4% (20/46). Documented eradication was achieved among 24 of the 33 patients who had control blood culture samples (72.7%), and mean eradication time was 7.6 days. Echocardiography was performed in 14% (7/50) and ophthalmic examination in 8% (4/50). Conclusion: Although C. albicans appears to be the dominant strain in patients with candidemia, frequencies of other strains are increasing. Early diagnosis and treatment of patients with candidemia is of vital importance due to high mortality and morbidity rates.Article Citation - WoS: 2Citation - Scopus: 2Optimization of Elisa and Immunoblot Methods for the Detection of Igg Antibodies Against Old World Hantaviruses in Wild Rodents(Ankara Microbiology Soc, 2016-04-07) Polat, Ceylan; Karatas, Ahmet; Sozen, Mustafa; Matur, Ferhat; Abacioglu, Hakan; Oktem, Mehmet Ali; Öktem, İbrahim Mehmet AliHantaviruses infect humans via inhalation of viral particles in infected rodents' secretions such as saliva, urine and faeces or via direct contact with infected rodents. The rodent species that are known as the carriers of Dobrava (DOBV), Puumala (PUUV), Saaremaa (SAAV), Tula (TULV) and Seoul (SEOV) viruses are found in our country. The presence of specific antibodies against hantaviruses have been demonstrated in rodents collected from Black Sea and Aegean Regions of Turkey in 2004 for the first time. The first hantavirus-related hemorrhagic fever with renal syndrome (HFRS) cases were reported in Black Sea region in 2009. The determination of the hantavirus prevalence in wild life and rodent populations in the field is crucial for the information about hantavirus-related cases and to clarify the state of risk. There is no commercial product optimized for the screening of rodent serum samples in terms of HFRS agents like DOBV and PUUV that are widely seen in Eurasia as well as Turkey. In this study, the antigens belonging to the commercial enzyme-linked immunoassay (ELISA) and immunoblot tests that are produced for the screening of human sera were used for the development of antibody screening tests against hantavirus in rodent sera and were optimized. The most appropriate serum and conjugate dilutions were determined for the optimization of ELISA (Anti-Hantavirus Pool ELISA; Euroimmun, Germany) and immunoblot (Euroline Anti-Hanta Profile 1 strips; Euroimmun, Germany) methods. Optimized ELISA method was used for the screening and optimized immunoblot method was used for the confirmation. A total of 84 wild rodent sera that belonged to Apodemus and Microtus species were evaluated with this procedure and the cut-off value, sensitivity and specificity of optimized ELISA method were determined. For the optimization of ELISA 1/50, 1/100 and 1/200 serum dilutions and 1/10.000, 1/20.000 and 1/40.000 conjugate dilutions were tested. For the optimization of immunoblot, 1/50 and 1/100 serum dilutions and 1/5.000 and 1/10.000 conjugate dilutions were tested. The horseradish peroxidase conjugated goat anti-mouse IgG for ELISA and the alkaline phosphatase conjugated goat anti-mouse IgG for immunoblot were used. We followed the manufacturer's recommendations for the incubation parameters, substrate and the number of washes. 1/50 serum dilution and 1/10.000 conjugate dilution for ELISA and 1/100 serum dilution and 1/5.000 conjugate dilution for immunoblot were determined as optimal concentrations. By using the optimized ELISA, 26.2% (22/84) of rodents were found positive for hantavirus antibodies according the determined cut-off value (OD450/620: 0.325). By using immunoblot as a confirmatory test, 20 out of 22 ELISA positive samples could be studied because of the insufficient amount of sera and 17 of them was found positive in terms of DOBV antibodies. Of these rodents 11 were Apodemus flavicollis, three were Apodemus agrarius, two were Microtus guentheri and one was Apodemus sylvaticus. When the results of ELISA were compared to immunoblot results, the optimized ELISA's sensitivity and specificity were found as 100% and 95%, respectively. In this study, a method that can be used in the screening of rodent sera was constituted which uses commercial antigens that can be provided easily, gives fast and reliable results. Similar serological methods optimized for different types of rodents are of great importance for the realization of active follow-up and monitoring of the studies in the field.Article Citation - WoS: 1Citation - Scopus: 2Evaluation of Treatment Safety in Patients With Atrial Fibrillation on Edoxaban Therapy in Real-Life in Turkey Study: Design and Rationale(Aves, 2022-03-16) Türk Uğur Önsel; Alioglu, Emin; Mavioglu, Zafer; Diker, Erdem; Ozpelit, Ebru; De Caterina, Raffaele; Türk, Uğur Önsel; Caterina, Raffaele DeObjective: Safety and effectiveness of edoxaban was demonstrated in phase III, Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48 (ENGAGE-AF-TIMI 48) trial and is being confirmed in the post-authorization Edoxaban Treatment in routiNe clinical prActice for patients with Atrial Fibrillation in Europe (ETNA-AF-Europe) study in patients with atrial fibrillation. However. any post-authorization safety study focusing on the safety of edoxaban treatment in Turkey with a prospective design has not been performed yet. The Evaluation of Treatment Safety in Patients with Atrial Fibrillation on Edoxaban Therapy in Real-Life in Turkey (ETAF-TR) study is designed to evaluate the safety and effectiveness of edoxaban treatment in atrial fibrillation in routine practice. The present article describes the design and rationale for the ETAF-TR Study. Methods: The ETAF-TR (NCT04594915) is a national. multicenter. prospective, observational study that enrolled 858 patients from 32 centers. The primary outcome of the ETAF-TR study is any overt bleeding (consisting of major bleeding or clinically relevant nonmajor bleeding or any bleeding that does not meet this definition but is considered as overt bleeding by the participating physician). Effectiveness, treatment persistence. and posology will also be evaluated in an explorative manner. The overall duration of follow-up will be 1 year: the first patient was enrolled in August 2020. Conclusions: Results of ETAF-TR wilt add data from clinical practice to those from ENGAGE-AF trial and also ETNA-AF study. Comparing their results will enable to test the external validity of ENGAGE-AF trial in the country conditions.Article Citation - WoS: 1Comparison of Pulmonary Functions, Physical Activity Level and Quality of Life in Obese and Pre-Obese Individuals(Aves, 2017-11-30) Aktan, Ridvan; Ozalevli, SevgiObjective: There are studies regarding pulmonary functions of obese individuals in literature; however, there is insufficient data regarding pre-obese individuals. This study aimed to compare the pulmonary functions, physical activity levels, and health-related quality of life (HRQOL) of obese and pre-obese individuals. Methods: The characteristics of 62 subjects participating in the study were recorded All subjects were evaluated using pulmonary function tests (PFT), short form-36 health survey (SF-36), obesity and weight loss quality of life measure (OWLQOL), international physical activity questionnaires (IPAQ), and modified medical research council (mMRC) scale. Results: The severity of perceived dyspnea in obese subjects was significantly higher than that in pre-obese subjects. The PFT parameters (FVC, FEV 1, PEF, FEF 25-75, FEF 25-75 %, MVV, and MVV%) were significantly lower in obese subjects. Although individuals in both groups were inactive, the inactivity levels in obese subjects were significantly higher. HRQOL scores were significantly lower in obese individuals. The body mass index (BMI) was significantly correlated with dyspnea severity, SF-36 subscores, OWLQOL scores, and PFT parameters. Conclusion: While an increasing BMI has an adverse effect on the pulmonary functions of pre-obese individuals, increased BMI coupled with reduced pulmonary functions causes a decrease in the physical activity levels and reduces HRQOL of obese individuals.